13 research outputs found

    Fludarabine, cytarabine, granulocyte colony-stimulating factor, and idarubicin with gemtuzumab ozogamicin improves event-free survival in younger patients with newly diagnosed aml and overall survival in patients with npm1 and flt3 mutations

    Get PDF
    Purpose To determine the optimal induction chemotherapy regimen for younger adults with newly diagnosed AML without known adverse risk cytogenetics. Patients and Methods One thousand thirty-three patients were randomly assigned to intensified (fludarabine, cytarabine, granulocyte colony-stimulating factor, and idarubicin [FLAG-Ida]) or standard (daunorubicin and Ara-C [DA]) induction chemotherapy, with one or two doses of gemtuzumab ozogamicin (GO). The primary end point was overall survival (OS). Results There was no difference in remission rate after two courses between FLAG-Ida + GO and DA + GO (complete remission [CR] + CR with incomplete hematologic recovery 93% v 91%) or in day 60 mortality (4.3% v 4.6%). There was no difference in OS (66% v 63%; P = .41); however, the risk of relapse was lower with FLAG-Ida + GO (24% v 41%; P < .001) and 3-year event-free survival was higher (57% v 45%; P < .001). In patients with an NPM1 mutation (30%), 3-year OS was significantly higher with FLAG-Ida + GO (82% v 64%; P = .005). NPM1 measurable residual disease (MRD) clearance was also greater, with 88% versus 77% becoming MRD-negative in peripheral blood after cycle 2 (P = .02). Three-year OS was also higher in patients with a FLT3 mutation (64% v 54%; P = .047). Fewer transplants were performed in patients receiving FLAG-Ida + GO (238 v 278; P = .02). There was no difference in outcome according to the number of GO doses, although NPM1 MRD clearance was higher with two doses in the DA arm. Patients with core binding factor AML treated with DA and one dose of GO had a 3-year OS of 96% with no survival benefit from FLAG-Ida + GO. Conclusion Overall, FLAG-Ida + GO significantly reduced relapse without improving OS. However, exploratory analyses show that patients with NPM1 and FLT3 mutations had substantial improvements in OS. By contrast, in patients with core binding factor AML, outcomes were excellent with DA + GO with no FLAG-Ida benefit

    Directions to meeting

    No full text

    Structure and Meaning in Models of Breast and Cervical Cancer Risk Factors: A Comparison of Perceptions among Latinas, Anglo Women, and Physicians

    No full text
    This article reports on a study of perceptions of breast and cervical cancer risk factors among 27 U.S.-born Chicanas, 39 Mexican and 28 Salvadoran immigrants, 27 Anglo women, and 30 physicians in northern Orange County, California. In open-ended responses explaining why women might be at risk for both cancers, Latinas expressed two general themes: physical stress and trauma to the body, and behavior and lifestyle choices. Interviewees ranked the specific risk factors that they themselves mentioned. Cultural consensus of ranked data revealed that Mexican and Salvadoran immigrants had a model of cancer risks that was different from those of Anglo women and physicians. U.S.-born Chicanas were bicultural in their views, which overlapped with both Mexican women's and Anglo women's views, but less so with physicians' views. Comparing views about the two cancers revealed that general themes apply across both cancers, that Latina immigrants agreed less on the risk factors for cervical cancer than for breast cancer, and that there is a consistent pattern in the different ways Latinas, Anglos, and physicians perceive risk factors for both cancers

    iREDS

    No full text
    The University of California, Riverside (UCR) proposes a new campus initiative for the cultivation of ethical climates and practices in STEM research, using a novel online communications platform combined with a project-based training designed to be compatible with that platform. We plan to deploy and evaluate a campus-wide interdisciplinary project, Institutional Re-engineering Ethical Discourse in STEM (iREDS), by examining the effects of two randomized interventions, separately and combined, and in comparison with a fourth control group receiving the standard ethics training that currently exists on campus. The overarching goal is to re-engineer ethical discourse in STEM research at the university. The project's methods use a randomized control trial (RCT) two factor design that enables both between-lab comparison among randomly assigned intervention groups and within-lab comparison over time. iREDS will introduce to selected groups of labs a free, web-based scientific communication platform, the Open Science Framework (OSF), as an everyday part of lab project workflows. The standard OSF training and its use in practice should foster more fluent communication within research groups, enhancing research methods transparency. Two other groups of labs will engage in project-based, peer-delivered ethics training, either as stand-alone or as an integrated supplement to the OSF. The peer-delivered ethics training engages lab personnel in deliberations on the ethical dimensions of the federally-funded projects in which they are engaged. Effects of the full treatment, project-based training as part of the OSF platform will be compared with OSF-only training (no project-based supplement), the stand alone project-training (no OSF presence), and a group of labs exposed to neither. We will combine quantitative comparisons of outcomes between these groups with an in-depth ethnographic study of representative labs; the ethnographic study will provide insights into the lab-level determinants of ethical climate and into the sources of heterogeneous responses to our interventions
    corecore